Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Merck & Co. logo
Merck & Co.MRK
$341.11B+34.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
AbbVie logo
AbbVieABBV
$460.96B+24.7%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$2.8B+110%
Incyte logo
IncyteINCY
$15.31B+55.9%

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Calculated from Arcus Biosciences’s reported figures.

$2.7Bmarket cap+$113.0Mtotal debt−$201.0Mcash and equivalents=$2.62B

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's enterprise value?
Arcus Biosciences (RCUS) reported enterprise value of $2.62B in Q1 2026.
How has Arcus Biosciences's enterprise value changed year-over-year?
Arcus Biosciences's enterprise value increased by 274.8% year-over-year, from $698.86M to $2.62B.
What is the long-term trend for Arcus Biosciences's enterprise value?
Over 5 years (2020 to 2025), Arcus Biosciences's enterprise value has grown at a 11.9% compound annual growth rate (CAGR), from $1.67B to $2.92B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.